gms | German Medical Science

23rd Annual Meeting of the German Retina Society

German Retina Society

24.09. - 25.09.2010, Freiburg

Potentials of anti-VEGF therapy in neovascular glaucoma

Meeting Abstract

Search Medline for

  • Andreas Lipski - University Eye Clinic Essen
  • N. Bornfeld - University Eye Clinic Essen
  • B. Jurklies - University Eye Clinic Essen

German Retina Society. 23rd Annual Conference of the German Retina Society. Freiburg i. Br., 24.-25.09.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. Doc10rg43

doi: 10.3205/10rg43, urn:nbn:de:0183-10rg432

This is the translated version of the article.
The original version can be found at: http://www.egms.de/de/meetings/rg2010/10rg43.shtml

Published: September 21, 2010

© 2010 Lipski et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Background: Causal therapeutic approaches to neovascular glaucome e.g. in diabetic retinopathy include destructive laser- and kryotechniques of both the retina and ciliary body. Although anti-VEGF therapy widens the therapeutic spectrum, its efficacy remains unproven.

Methods: Case presentations, review of the literature.

Results: An uncomparable potential to temporarily resolve neovascular vessels following intraocular phamacotherapy using Avastin justifies rapid and lasting introduction into the therapeutic catalogue in neovascular glaucoma; an irreplaceable time advantage in the long term therapy of the disease may result.

Conclusion: As the pathogenesis of neovascular glaucoma is not influenced causally or longer-lasting by intraocular Avastin, adjunctive and prompt application of the aforementioned established treatment modalities may help to approve or refund anti-VEGF therapy in neovascular glaucoma.